Activity Details

Free CME
0.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
20 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education


This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Target Audience

The target audience for this activity is for community and academic medical oncologists, hematologists, advanced practitioners, and other clinicians who treat patients with lymphoma.

Learning Objectives

After completing this activity, participants should be better able to:

  • Review clinical trial data that led to approval of CAR T-cell–based therapies for the treatment of patients with lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with lymphoma, including various combination strategies being examined
  • Develop strategies to mitigate adverse events often encountered with the use of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity

Activity Description

Expert Insights is an interview involving 2 world renowned experts actively engaged in treatment of patients with lymphoma. This discussion features expert summary and interpretation of data presented during the 2018 Pan Pacific Lymphoma Conference in Hawaii, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

CD19-targeted CAR T cells have emerged as a highly effective therapy in patients with NHL. However, multiple CAR T-cell technologies are under investigation, all with various doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. Thus, clinicians treating patients with aggressive NHL need expert guidance to evaluate clinical data on CAR T-cell therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.


Julie M. Vose, MD, MBA - Moderator
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Grants/Research Support: Acerta Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite Pharma, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Seattle Genetics, Inc.

Consultant Fees, Honorarium: AbbVie Inc., Epizyme, Inc., Karyopharm Therapeutics, Legend Pharmaceuticals, Novartis, Roche, Sandoz, Vaniam Group LLC

Sattva S. Neelapu, MD
Deputy Department Chair ad interim
Director of Laboratory and Translational Research
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Research Support, Advisor: Acerta Pharma, Bristol-Myers Squibb Company, Cellectis, Gilead, Karus, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Poseida

Consultant, Advisor: Celgene Corporation, Kite, A Gilead Company, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Novartis, Unum Therapeutics

Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Celgene Corporation and Kite, A Gilead Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP

Bio Ascend

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.